Clincosm LogoSign in Get a demo

Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species

Sponsor
University of Pittsburgh (Other)
Overall Status
Completed
CT.gov ID
NCT00518661
Collaborator
(none)
500
Enrollment
1
Location
124
Actual Duration (Months)
4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a retrospective chart review. This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This is a retrospective chart review. This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed. This research is (c) important because identification of risk factors may allow earlier initiation of appropriate therapy in patients infected with these bacteria. Additionally, we will identify whether horizontal spread is responsible for this increasing trend.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    500 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Risk Factors for Quinolone Resistance Among Extended-Spectrum Beta-Lactamase-Producing Klebsiella Species
    Actual Study Start Date :
    Aug 1, 2007
    Actual Primary Completion Date :
    Dec 1, 2017
    Actual Study Completion Date :
    Dec 1, 2017

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • must be quinolone resistant among ESBL producing klebsiella species
      Exclusion Criteria:
      • Those not meeting entry criteria

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 University of Pittsburgh Medical Center Pittsburgh Pennsylvania United States 15213

      Sponsors and Collaborators

      • University of Pittsburgh

      Investigators

      • Principal Investigator: Brian Potoski, PharmD, University of Pittsburgh

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      Yohei Doi, Associate Professor, University of Pittsburgh
      ClinicalTrials.gov Identifier:
      NCT00518661
      Other Study ID Numbers:
      • PRO07070356
      • investigator funding
      First Posted:
      Aug 21, 2007
      Last Update Posted:
      Jun 14, 2018
      Last Verified:
      Jun 1, 2018
      Keywords provided by Yohei Doi, Associate Professor, University of Pittsburgh
      quinolone resistance
      ESBL
      Klebsiella species
      Infection
      Additional relevant MeSH terms:
      Klebsiella Infections

      Study Results

      No Results Posted as of Jun 14, 2018